Atara receives action date for tabcel
Thousand Oaks-based Atara Biotherapeutics announced that its partner, Pierre Fabre Pharmaceuticals, received acceptance by the U.S. Food and Drug Administration of the Biologics License Application for tabelecleucel, Atara’s lead product, on Oct. 14. With the notice, the FDA also set a target action date for the drug on March 31. Tabelecleucel, sold under the brand Read More →
Moorpark College, CSUCI partner on new bachelor program in cybersecurity
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Rona inks deal worth up to $1.16B to license obesity drug
Rona Therapeutics, a world-leading RNAi therapeutics company dedicated to addressing cardiometabolic, obesity and degenerative diseases with a next-generation RNA technology platform, announced it has entered into an exclusive worldwide licensing agreement worth up to $1.16 billion with Roche for its investigational obesity drug candidate. Rona is based in Shanghai, China, but maintains a U.S. headquarters Read More →
Pearly’s new CEO aims to continue growth within the startup’s niche market
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
AeroVironment sues former employees in trade secrets case
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
805 tech: A star TMP alumni shares insights on AI industry
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Atara resubmits Ebvallo BLA to FDA
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
